The Era of Rebate Rip-offs Is Over (Maybe)
Eli Lilly & Co. is cutting the list prices for Humalog and Humulin, its two biggest-selling insulin products by 70%. The price cuts will...
top of page
News
- Mar 1
Drug-Prices Investigation Focused on Middlemen Opens in Congress
House Republicans have launched an investigation into the companies that manage drug benefits, dialing up the scrutiny of the middlemen...
- Feb 28
Video: Senators Criticize PBMs at Recent Hearing
The Senate Commerce Committee held a hearing on Feb. 16 to discuss how pharmacy benefit managers (PBMs) impact patients and community...
- Feb 17
PBMs Get Heavy Dose of Criticism at Senate Hearing
Pharmacy benefit managers (PBMs) came under some harsh attacks and critiques today at a Senate hearing about legislation that would add...
- Feb 17
Senate Committee Puts PBMs Under the Microscope
Pharmacy benefit managers (PBMs) -- middlemen between pharmacies, health insurers, and drug companies -- are responsible for driving up...
- Feb 17
Senate begins quest to demystify PBMs' practices as it mulls legislation
The Senate Commerce Committee today held a hearing in which members on both sides of the aisle raised questions about the practices of...
- Feb 17
'In the crosshairs': PBM reform effort intensifies on Capitol Hill
The drumbeat of calls to enact reforms to pharmaceutical middlemen is growing louder after years of largely unsuccessful attempts by...
- Feb 16
Chairman of the Board Response to U.S. Senators’ Efforts to Hold PBMs Accountable
Doug Dority, Chairman of the Board of the PBM Accountability Project penned a letter to Senators Maria Cantwell and Chuck Grassley in...
- Feb 16
Senators question why PBMs 'even exist' in heated hearing amid push for reform
Senators pilloried the lack of transparency from pharmacy benefit managers during a hearing Thursday, as lawmakers hope to pass reforms...
- Feb 16
Tough day for PBMs
It's never pleasant for your industry when senators are publicly musing at a hearing about whether your companies should exist, but...
- Feb 15
How 3 companies came to dominate the PBM market
When you think of industries dominated by a few powerful players (*cough* tech *cough*), the pharmacy benefit manager (PBM) industry...
- Feb 14
Mark Cuban Assails PBMs at AAM meeting
Mark Cuban made scathing, profanity-laced remarks about pharmacy benefit managers (PBMs) and heaped praised on drug manufacturers...
- Feb 14
Health care giant Centene settles with another state, California
Medicaid managed-care giant Centene has agreed to pay California $215 million to settle a drug-pricing scandal related to one that was...
- Feb 8
PBMA Chairman of the Board Response to State of the Union address
Doug Dority, Chairman of the Board of the PBM Accountability Project penned a letter to members of the Biden Administration in response...
- Feb 8
Biden’s SOTU Targets Drug Companies, But Misses Opportunity To Challenge Health Insurers And PBMs
President Biden’s State of the Union Address hammered home the point that drug prices must come down. He reminded viewers that he and his...
- Feb 7
Need a new drug? You may be asked to ‘fail’ an old drug first
Many patients seeking better drug treatments are being rejected by their insurance companies. The reason: Patients must first “fail” at...
- Feb 7
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
The politics and policies of high drug prices have been swirling around for years. But recently, attention has shifted to PBMs, which...
- Feb 2
Bipartisan Policy Center Brief: High Drug Prices: Are PBMs the Right Target?
Pharmacy benefit managers (PBMs) may be Congress’ next target for high prescription drug prices. There is evidence that PBMs may be...
- Feb 1
Centene to pay $66.5 million in Indiana Medicaid drug pricing settlement
Health care services company Centene Corp. will pay Indiana nearly $66.5 million to resolve allegations that it overcharged the state’s...
- Jan 21
Corporate bad actors make billions from abusing program designed to help low-income patients | Guest
Large hospital systems and pharmacy benefit managers have been taking advantage of a federal program for far too long, netting billions...
- Jan 20
Why Now Is the Time for Health Plans to Take Control of Pharmacy Benefits
Health plans today must consider what they want out of their pharmacy benefits and how to achieve something better for their members. And...
- Jan 15
It is Time for Policymakers to Protect Patients from Predatory Practices of Insurers and PBMs
Although per capita patient out-of-pocket (OOP) spending on prescription medications has dropped, averages are deceiving. In the U.S., a...
- Jan 14
Lawmakers are readying fresh attacks on pharmacy middlemen
As key lawmakers gear up for the new Congress, there’s at least one industry that will be caught in the crosshairs: pharmacy benefit...
- Jan 13
With the FTC’s more expansive approach to antitrust, PBMs are in the crosshairs
WASHINGTON — The Democrats leading the Federal Trade Commission are hoping to expand the agency’s authority to crack down on unfair...
bottom of page